Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback